These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 18439051)

  • 1. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.
    D'Souza AO; Smith MJ; Miller LA; Doyle J; Ariely R
    J Manag Care Pharm; 2008 Apr; 14(3):291-301. PubMed ID: 18439051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence.
    Hughes DA; Dubois D
    Pharmacoeconomics; 2004; 22(16):1047-59. PubMed ID: 15524493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence with overactive bladder pharmacotherapy in a Medicaid population.
    Shaya FT; Blume S; Gu A; Zyczynski T; Jumadilova Z
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S121-9. PubMed ID: 16161385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates.
    Nitz NM; Jumadilova Z; Darkow T; Frytak JR; Bavendam T
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S130-9. PubMed ID: 16161386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder.
    Varadharajan S; Jumadilova Z; Girase P; Ollendorf DA
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S140-9. PubMed ID: 16161387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin.
    Perfetto EM; Subedi P; Jumadilova Z
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S150-7. PubMed ID: 16161388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective evaluation of outcomes in patients with overactive bladder receiving tolterodine versus oxybutynin.
    Jumadilova Z; Varadharajan S; Girase P; Ollendorf DA
    Am J Health Syst Pharm; 2006 Dec; 63(23):2357-64. PubMed ID: 17106009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program.
    Yu YF; Nichol MB; Yu AP; Ahn J
    Value Health; 2005; 8(4):495-505. PubMed ID: 16091027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder.
    Bolge SC; McDonnell DD; Chen A; Wan GJ
    Curr Med Res Opin; 2007 Aug; 23(8):1903-12. PubMed ID: 17610806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder.
    Getsios D; Caro JJ; Ishak KJ; El-Hadi W; Payne K
    Clin Ther; 2004 Mar; 26(3):431-8. PubMed ID: 15110136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
    Wagg A; Compion G; Fahey A; Siddiqui E
    BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial.
    Homma Y; Paick JS; Lee JG; Kawabe K;
    BJU Int; 2003 Nov; 92(7):741-7. PubMed ID: 14616458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
    Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
    Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Overactive Bladder Step Therapy Policies on Medication Utilization and Expenditures Among Treated Medicare Members.
    Abbass IM; Caplan EO; Ng DB; Kristy R; Schermer CR; Bradt P; Collins JM; Chan WM; Suehs BT
    J Manag Care Spec Pharm; 2017 Jan; 23(1):27-37. PubMed ID: 28025920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
    Cardozo L; Thorpe A; Warner J; Sidhu M
    BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial.
    Homma Y; Kawabe K
    World J Urol; 2004 Oct; 22(4):251-6. PubMed ID: 15455256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review.
    Rovner ES; Wein AJ
    Eur Urol; 2002 Jan; 41(1):6-14. PubMed ID: 11999467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of tolterodine with standard treatment in pediatric patients with non-neurogenic dysfunctional voiding/over active bladder: a systematic review.
    Medhi B; Mittal N; Bansal D; Prakash A; Sarangi SC; Nirthi B
    Indian J Physiol Pharmacol; 2013; 57(4):343-53. PubMed ID: 24968572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
    Rovner ES; Rackley R; Nitti VW; Wang JT; Guan Z;
    Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.